Compare Cipla with Pfizer - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs PFIZER - Comparison Results

CIPLA     Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA PFIZER CIPLA/
PFIZER
 
P/E (TTM) x 21.6 35.7 60.5% View Chart
P/BV x 2.4 6.1 39.5% View Chart
Dividend Yield % 0.7 0.6 119.3%  

Financials

 CIPLA   PFIZER
EQUITY SHARE DATA
    CIPLA
Mar-19
PFIZER
Mar-19
CIPLA/
PFIZER
5-Yr Chart
Click to enlarge
High Rs6783,840 17.7%   
Low Rs4842,080 23.3%   
Sales per share (Unadj.) Rs198.2455.0 43.6%  
Earnings per share (Unadj.) Rs18.593.8 19.8%  
Cash flow per share (Unadj.) Rs35.0109.4 32.0%  
Dividends per share (Unadj.) Rs3.0022.50 13.3%  
Dividend yield (eoy) %0.50.8 67.9%  
Book value per share (Unadj.) Rs186.3658.2 28.3%  
Shares outstanding (eoy) m805.7045.75 1,761.1%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.96.5 45.0%   
Avg P/E ratio x31.431.6 99.4%  
P/CF ratio (eoy) x16.627.1 61.4%  
Price / Book Value ratio x3.14.5 69.3%  
Dividend payout %16.224.0 67.5%   
Avg Mkt Cap Rs m468,031135,420 345.6%   
No. of employees `00022.62.6 860.7%   
Total wages/salary Rs m28,5653,238 882.1%   
Avg. sales/employee Rs Th7,053.17,911.4 89.2%   
Avg. wages/employee Rs Th1,261.51,230.9 102.5%   
Avg. net profit/employee Rs Th659.11,630.7 40.4%   
INCOME DATA
Net Sales Rs m159,71020,815 767.3%  
Other income Rs m4,7661,674 284.7%   
Total revenues Rs m164,47522,489 731.4%   
Gross profit Rs m30,9735,712 542.2%  
Depreciation Rs m13,263714 1,857.8%   
Interest Rs m1,68473 2,310.4%   
Profit before tax Rs m20,7916,599 315.1%   
Minority Interest Rs m-1720-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,6952,309 246.7%   
Profit after tax Rs m14,9244,291 347.8%  
Gross profit margin %19.427.4 70.7%  
Effective tax rate %27.435.0 78.3%   
Net profit margin %9.320.6 45.3%  
BALANCE SHEET DATA
Current assets Rs m124,26627,167 457.4%   
Current liabilities Rs m37,7158,917 423.0%   
Net working cap to sales %54.287.7 61.8%  
Current ratio x3.33.0 108.1%  
Inventory Days Days9168 133.6%  
Debtors Days Days9530 315.1%  
Net fixed assets Rs m105,1908,862 1,187.0%   
Share capital Rs m1,611458 352.2%   
"Free" reserves Rs m148,51129,656 500.8%   
Net worth Rs m150,12330,113 498.5%   
Long term debt Rs m38,30125 153,202.8%   
Total assets Rs m239,63339,400 608.2%  
Interest coverage x13.391.5 14.6%   
Debt to equity ratio x0.30 30,731.2%  
Sales to assets ratio x0.70.5 126.2%   
Return on assets %6.911.1 62.6%  
Return on equity %9.914.2 69.8%  
Return on capital %11.822.1 53.5%  
Exports to sales %34.70-   
Imports to sales %00-   
Exports (fob) Rs m55,419NA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m57,410428 13,404.0%   
Fx outflow Rs m19,041786 2,421.3%   
Net fx Rs m38,368-358 -10,714.4%   
CASH FLOW
From Operations Rs m16,911978 1,729.0%  
From Investments Rs m-16,687351 -4,751.4%  
From Financial Activity Rs m-3,487-1,099 317.5%  
Net Cashflow Rs m-3,451231 -1,495.3%  

Share Holding

Indian Promoters % 16.0 0.0 -  
Foreign collaborators % 20.8 63.9 32.6%  
Indian inst/Mut Fund % 12.2 7.5 162.7%  
FIIs % 23.7 4.9 483.7%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 23.7 110.5%  
Shareholders   161,166 85,207 189.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   AUROBINDO PHARMA  ORCHID PHARMA LTD  GSK PHARMA  J.B.CHEMICALS  SHASUN PHARMA  

Compare CIPLA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 674 Points Lower; Banking and Finance Stocks Witness Selling(Closing)

Indian share markets witnessed selling pressure throughout the day and ended lower. Investors were worried about the economic impact and uncertainty over the coronavirus pandemic.

Related Views on News

PFIZER Announces Quarterly Results (3QFY20); Net Profit Up 5.4% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, PFIZER has posted a net profit of Rs 1 bn (up 5.4% YoY). Sales on the other hand came in at Rs 5 bn (up 4.7% YoY). Read on for a complete analysis of PFIZER's quarterly results.

CIPLA Announces Quarterly Results (3QFY20); Net Profit Up 9.4% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, CIPLA has posted a net profit of Rs 4 bn (up 9.4% YoY). Sales on the other hand came in at Rs 44 bn (up 9.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (2QFY20); Net Profit Up 31.2% (Quarterly Result Update)

Nov 14, 2019 | Updated on Nov 14, 2019

For the quarter ended September 2019, CIPLA has posted a net profit of Rs 5 bn (up 31.2% YoY). Sales on the other hand came in at Rs 44 bn (up 9.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

PFIZER Announces Quarterly Results (2QFY20); Net Profit Up 61.0% (Quarterly Result Update)

Oct 29, 2019 | Updated on Oct 29, 2019

For the quarter ended September 2019, PFIZER has posted a net profit of Rs 2 bn (up 61.0% YoY). Sales on the other hand came in at Rs 6 bn (up 9.1% YoY). Read on for a complete analysis of PFIZER's quarterly results.

CIPLA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 9, 2019 | Updated on Sep 9, 2019

Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

More Views on News

Most Popular

Sorry Warren Buffett, I'm Following This Man Instead of You in 2020(The 5 Minute Wrapup)

Mar 30, 2020

This man warned of an impending market correction while everyone else was celebrating the renewed optimism in early 2020...

The Biggest Trading Opportunity of 2020 is Here...

Mar 26, 2020

India's #1 trader, Vijay Bhambwani, talks about a hugely profitable trading opportunity which you must know about today!

A Big Trading Opportunity is Coming Your Way Soon(Fast Profits Daily)

Mar 25, 2020

I see a big opportunity to make fast profits on the horizon.

Coronavirus Sell-off Is a Perfect Time to 'Lockdown' this 'Crorepati' Stock(Profit Hunter)

Mar 24, 2020

Coronavirus crisis and panic selling has brought this quality smallcap to multiyear lows, making it a great bargain.

One Stock that is All Charged Up for the Post Coronavirus Rebound(The 5 Minute Wrapup)

Apr 1, 2020

A stock with strong moat is currently trading near 5-year lows.

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Apr 3, 2020 (Close)

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS